Structure-function analyses unravel distinct effects of allosteric inhibitors of HIV-1 integrase on viral maturation and integration

Recently, a new class of HIV-1 integrase (IN) inhibitors with a dual mode of action, called IN-LEDGF/p75 allosteric inhibitors (INLAIs), was described. Designed to interfere with the IN-LEDGF/p75 interaction during viral integration, unexpectedly, their major impact was on virus maturation. This activity has been linked to induction of aberrant IN multimerization, whereas inhibition of the IN-LEDGF/p75 interaction accounts for weaker antiretroviral effect at integration. Because these dual activities result from INLAI binding to IN at a single binding site, we expected that these activities co-evolved together, driven by the affinity for IN. Using an original INLAI, MUT-A, and its activity on an Ala-125 (A125) IN variant, we found that these two activities on A125-IN can be fully dissociated: MUT-A–induced IN multimerization and the formation of eccentric condensates in viral particles, which are responsible for inhibition of virus maturation, were lost, whereas inhibition of the IN-LEDGF/p75 interaction and consequently integration was fully retained. Hence, the mere binding of INLAI to A125 IN is insufficient to promote the conformational changes of IN required for aberrant multimerization. By analyzing the X-ray structures of MUT-A bound to the IN catalytic core domain (CCD) with or without the Ala-125 polymorphism, we discovered that the loss of IN multimerization is due to stabilization of the A125-IN variant CCD dimer, highlighting the importance of the CCD dimerization energy for IN multimerization. Our study reveals that affinity for the LEDGF/p75-binding pocket is not sufficient to induce INLAI-dependent IN multimerization and the associated inhibition of viral maturation.

[1]  B. Berkhout,et al.  The HIV-1 integrase-LEDGF allosteric inhibitor MUT-A: resistance profile, impairment of virus maturation and infectivity but without influence on RNA packaging or virus immunoreactivity , 2017, Retrovirology.

[2]  M. Kvaratskhelia,et al.  Allosteric HIV-1 Integrase Inhibitors Lead to Premature Degradation of the Viral RNA Genome and Integrase in Target Cells , 2017, Journal of Virology.

[3]  F. Bushman,et al.  Structural Basis for Inhibitor-Induced Aggregation of HIV Integrase , 2016, PLoS biology.

[4]  K. White,et al.  Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile , 2016, Antimicrobial Agents and Chemotherapy.

[5]  P. Bieniasz,et al.  HIV-1 Integrase Binds the Viral RNA Genome and Is Essential during Virion Morphogenesis , 2016, Cell.

[6]  J. Duan,et al.  Aligning Potency and Pharmacokinetic Properties for Pyridine-Based NCINIs. , 2016, ACS medicinal chemistry letters.

[7]  Suha M. Saleh,et al.  LEDGIN-mediated Inhibition of Integrase–LEDGF/p75 Interaction Reduces Reactivation of Residual Latent HIV , 2016, EBioMedicine.

[8]  F. Bushman,et al.  The Competitive Interplay between Allosteric HIV-1 Integrase Inhibitor BI/D and LEDGF/p75 during the Early Stage of HIV-1 Replication Adversely Affects Inhibitor Potency. , 2016, ACS chemical biology.

[9]  A. Engelman,et al.  Distribution and Redistribution of HIV-1 Nucleocapsid Protein in Immature, Mature, and Integrase-Inhibited Virions: a Role for Integrase in Maturation , 2015, Journal of Virology.

[10]  Eugene Krissinel,et al.  Stock-based detection of protein oligomeric states in jsPISA , 2015, Nucleic Acids Res..

[11]  A. Engelman,et al.  The mechanism of H171T resistance reveals the importance of Nδ-protonated His171 for the binding of allosteric inhibitor BI-D to HIV-1 integrase , 2014, Retrovirology.

[12]  A. Engelman,et al.  Molecular mechanisms of retroviral integration site selection , 2014, Nucleic acids research.

[13]  P. Griffin,et al.  A Critical Role of the C-terminal Segment for Allosteric Inhibitor-induced Aberrant Multimerization of HIV-1 Integrase* , 2014, The Journal of Biological Chemistry.

[14]  A. Das,et al.  The Allosteric HIV-1 Integrase Inhibitor BI-D Affects Virion Maturation but Does Not Influence Packaging of a Functional RNA Genome , 2014, PloS one.

[15]  F. Bushman,et al.  Allosteric Inhibition of Human Immunodeficiency Virus Integrase , 2014, The Journal of Biological Chemistry.

[16]  A. Marchand,et al.  LEDGINs, non-catalytic site inhibitors of HIV-1 integrase: a patent review (2006 – 2014) , 2014, Expert opinion on therapeutic patents.

[17]  F. Bushman,et al.  A New Class of Multimerization Selective Inhibitors of HIV-1 Integrase , 2014, PLoS pathogens.

[18]  Araz Jakalian,et al.  Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1. , 2014, ACS medicinal chemistry letters.

[19]  J. Duan,et al.  Preclinical Profile of BI 224436, a Novel HIV-1 Non-Catalytic-Site Integrase Inhibitor , 2014, Antimicrobial Agents and Chemotherapy.

[20]  M. Wainberg,et al.  The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness , 2014, Retrovirology.

[21]  A. Saïb,et al.  Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage , 2013, Retrovirology.

[22]  S. Yant,et al.  Non-Catalytic Site HIV-1 Integrase Inhibitors Disrupt Core Maturation and Induce a Reverse Transcription Block in Target Cells , 2013, PloS one.

[23]  C. Weydert,et al.  LEDGINs inhibit late stage HIV-1 replication by modulating integrase multimerization in the virions , 2013, Retrovirology.

[24]  A. Engelman,et al.  The A128T Resistance Mutation Reveals Aberrant Protein Multimerization as the Primary Mechanism of Action of Allosteric HIV-1 Integrase Inhibitors* , 2013, The Journal of Biological Chemistry.

[25]  A. Engelman,et al.  Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation , 2013, Proceedings of the National Academy of Sciences.

[26]  A. Engelman,et al.  HRP2 determines the efficiency and specificity of HIV-1 integration in LEDGF/p75 knockout cells but does not contribute to the antiviral activity of a potent LEDGF/p75-binding site integrase inhibitor , 2012, Nucleic acids research.

[27]  D. Hazuda HIV integrase as a target for antiretroviral therapy , 2012, Current opinion in HIV and AIDS.

[28]  Stephen M. Shaw,et al.  Small-Molecule Inhibitors of the LEDGF/p75 Binding Site of Integrase Block HIV Replication and Modulate Integrase Multimerization , 2012, Antimicrobial Agents and Chemotherapy.

[29]  Xiaohong Liu,et al.  New Class of HIV-1 Integrase (IN) Inhibitors with a Dual Mode of Action , 2012, The Journal of Biological Chemistry.

[30]  A. Engelman,et al.  Multimode, Cooperative Mechanism of Action of Allosteric HIV-1 Integrase Inhibitors* , 2012, The Journal of Biological Chemistry.

[31]  Roman A. Laskowski,et al.  LigPlot+: Multiple Ligand-Protein Interaction Diagrams for Drug Discovery , 2011, J. Chem. Inf. Model..

[32]  Y. Pommier,et al.  Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143 , 2011, AIDS.

[33]  N. Pannu,et al.  REFMAC5 for the refinement of macromolecular crystal structures , 2011, Acta crystallographica. Section D, Biological crystallography.

[34]  A. Marchand,et al.  Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. , 2010, Nature chemical biology.

[35]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[36]  Alexei Vagin,et al.  Molecular replacement with MOLREP. , 2010, Acta crystallographica. Section D, Biological crystallography.

[37]  D. Moras,et al.  Structural basis for HIV‐1 DNA integration in the human genome, role of the LEDGF/P75 cofactor , 2009, The EMBO journal.

[38]  Francesca Ceccherini-Silberstein,et al.  Characterization and structural analysis of HIV-1 integrase conservation. , 2009, AIDS reviews.

[39]  Tommy F. Liu,et al.  Natural variation of HIV-1 group M integrase: Implications for a new class of antiretroviral inhibitors , 2008, Retrovirology.

[40]  A. Engelman,et al.  The Lentiviral Integrase Binding Protein LEDGF/p75 and HIV-1 Replication , 2008, PLoS pathogens.

[41]  Serge X. Cohen,et al.  Automated macromolecular model building for X-ray crystallography using ARP/wARP version 7 , 2008, Nature Protocols.

[42]  Gerhard Klebe,et al.  PDB2PQR: expanding and upgrading automated preparation of biomolecular structures for molecular simulations , 2007, Nucleic Acids Res..

[43]  M. Kozal,et al.  Natural Polymorphism of the HIV-1 Integrase Gene and Mutations associated with Integrase Inhibitor Resistance , 2007, Antiviral therapy.

[44]  K. Nagashima,et al.  Proteomic and Biochemical Analysis of Purified Human Immunodeficiency Virus Type 1 Produced from Infected Monocyte-Derived Macrophages , 2006, Journal of Virology.

[45]  Tarun Jain,et al.  An all atom energy based computational protocol for predicting binding affinities of protein–ligand complexes , 2005, FEBS letters.

[46]  Myriam Witvrouw,et al.  Integrase Mutants Defective for Interaction with LEDGF/p75 Are Impaired in Chromosome Tethering and HIV-1 Replication* , 2005, Journal of Biological Chemistry.

[47]  Marc C. Johnson,et al.  The stoichiometry of Gag protein in HIV-1 , 2004, Nature Structural &Molecular Biology.

[48]  P. Prevelige,et al.  Key interactions in HIV-1 maturation identified by hydrogen-deuterium exchange , 2004, Nature Structural &Molecular Biology.

[49]  Peter Briggs,et al.  A graphical user interface to the CCP4 program suite. , 2003, Acta crystallographica. Section D, Biological crystallography.

[50]  Zeger Debyser,et al.  HIV-1 Integrase Forms Stable Tetramers and Associates with LEDGF/p75 Protein in Human Cells* , 2003, The Journal of Biological Chemistry.

[51]  W. Delano The PyMOL Molecular Graphics System , 2002 .

[52]  D. Davies,et al.  Catalytic domain of human immunodeficiency virus type 1 integrase: identification of a soluble mutant by systematic replacement of hydrophobic residues. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[53]  F. Bushman,et al.  Domains of the integrase protein of human immunodeficiency virus type 1 responsible for polynucleotidyl transfer and zinc binding. , 1993, Proceedings of the National Academy of Sciences of the United States of America.